Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S Gensler, Nigil Haroon, Marina Magrey, Walter P Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip Van den Bosch, Thomas Vaux, Huji Xu
OBJECTIVES: Axial spondyloarthritis (axSpA) is a complex disease with diverse manifestations, for which new treatment options are warranted. BE MOBILE 1 (non-radiographic (nr)-axSpA) and BE MOBILE 2 (radiographic axSpA (r-axSpA)) are double-blind, phase 3 trials designed to evaluate efficacy and safety of bimekizumab, a novel dual interleukin (IL)-17A and IL-17F inhibitor, across the axSpA spectrum. METHODS: In parallel 52-week trials, patients with active disease were randomised 1:1 (nr-axSpA) or 2:1 (r-axSpA) to bimekizumab 160 mg every 4 weeks:placebo...
January 17, 2023: Annals of the Rheumatic Diseases